Biotechnology
Amgen beats Q2 earnings and revenue estimates
Amgen Inc. (NASDAQ: AMGN) reported second quarter 2019 adjusted EPS of $3.97 on revenue of $5.9 billion. Analysts had predicted…
Pfizer’s stock suffers as Q2 results and Mylan deal fail to impress Wall Street
Pfizer Inc.’s (NYSE: PFE) shares continue to trade in red after the company narrowly missed revenue estimates for the second…
Eli Lilly Q2 profit beats estimates, lifts FY19 forecast
Eli Lilly and Company (NYSE: LLY) swung to a profit in the second quarter of 2019 from a loss last…
Bristol-Myers Q2 earnings, revenue top Street; stock dips on weak guidance
Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported higher earnings and revenues for the second quarter, The results also…
Earnings: Alexion Pharma Q2 results top expectations; raises FY19 guidance
Alexion Pharmaceuticals (Nasdaq: ALXN) reported a 28% growth for its second-quarter earnings, helped by an increase in revenues. The results…
Is Advaxis exhausting its financial resources with the stock hitting a record low?
Advaxis Inc. (NASDAQ: ADXS) stock plunged to a record low of $1.54 on Tuesday as the late-stage biotech company has…
Top biotech stocks to be considered for investment this year
When the massive selloff battered Wall Street in the final months of 2018, biotechnology stocks were no exception. And, most…
Novavax Q1 earnings preview: Future plans on ResVax and NanoFlu will be the key focus points
Novavax Inc (NASDAQ: NVAX) is slated to report its first quarter 2019 earnings results after market closes on Thursday. Novavax…
Amgen Q1 earnings beat Street view; lifts full-year earnings guidance
Biotechnology firm Amgen (Nasdaq: AMGN) reported first-quarter earnings that increased from last year and exceeded estimates, while revenues remained unchanged. Meanwhile,…
Fennec Pharma stock plunges to all-time low
Fennec Pharmaceuticals Inc. (FENC) stock plunged to an all-time low of $4.69 on Tuesday. Investors were concerned about the future…
Aldeyra Therapeutics stock resumes trading, surges about 60% on positive trial results
After getting halted in Nasdaq for sometime, shares of Aldeyra Therapeutics (ALDX) resumed trading and climbed up about 60% during…